Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Expert Opinion on Investigational Drugs|September 21, 2013
The potential role of sunitinib targeting melanomasMatias E Valsecchi, Takami SatoReviews on Recent Clinical Trials|July 29, 2015
Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?Matias E Valsecchi, Enrique Díaz-CantónExpert Opinion on Investigational Drugs|June 13, 2015
Successes and setbacks of early investigational drugs for melanomaMarlana Orloff, Matias E Valsecchi, Takami SatoClinical Colorectal Cancer|July 21, 2010
Modifiable factors that influence colon cancer lymph node sampling and examinationMatias E Valsecchi, John Leighton, William TesterReviews on Recent Clinical Trials|June 25, 2015
Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast CancerMatias E Valsecchi, Gerrit Kimmey, Arvinder Bir, et al.Reviews on Recent Clinical Trials|March 31, 2016
Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?Marlana Orloff, Ryan Weight, Matias E Valsecchi, et al.Clinical Breast Cancer|November 26, 2009
Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitorsMatias E Valsecchi, Sherry C Pomerantz, Rebecca Jaslow, et al.Journal of Gastrointestinal Cancer|December 18, 2013
Recent treatment advances and novel therapies in pancreas cancer: a reviewMatias E Valsecchi, Enrique Díaz-Cantón, Máximo de la Vega, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysisMatias E Valsecchi, Damian Silbermins, Nicole de Rosa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2012
RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancerAgnieszka K Witkiewicz, Adam Ertel, Jeanne McFalls, et al.Pageof 3